First Hybrid International Symposium Acute Leukemias XVIII (ISAL XVIII) is organized by Association for Leukemia Research and Therapy eV / Verein fur Leukamieforschung und -Therapie e.V., German AML Cooperative Group (AMLCG) and will be held from Feb 20 - 23, 2022 at Klinikum Großhadern, Munich, Bavaria, Germany.
Target Audience:
The aim of this symposium is again to bring together a unique community of clinical scientists and researchers and to discuss the most recent findings in basic research and results of clinical studies and network with the top international experts in these fields.
Description:
While we are optimistic about the recent developments in fighting the pandemic, which will hopefully enable a high level of on-site participation, we are taking into account the current developments and want to be prepared on any changes. We are therefore pleased to inform you that the symposium will be continuing forward as a hybrid meeting.
The scientific program will start on Sunday, February 20, 2022 with a main focus on basic research while the following days will concentrate on translational research and clinical studies. You are cordially invited to use this forum to become updated on recent developments in the complex field of leukemia research and therapy. Satellite Symposia and Meet-the-Expert Sessions will deliver further chances to discuss advances and perspectives of basic science and treatment strategies.
The Symposium will focus on the following key areas:
• MS I: Epigenetic Changes in Acute Leukemias
• MS II: Clonal Evolution and Leukemic Stem Cells
• MS III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis
• MS IV: Novel Approaches and Targeted Therapies in AML
• MS VI: Risk adapted Therapy of AML
• MS VII: Biology and Treatment of APL
• MS VIII: Relevance of MRD in Acute Leukemias
• MS X: Immunotherapy for Acute Leukemias
• MS XI: ALL: Biology and Treatment Strategies
Share your research by submitting an abstract for the poster and the best of free contributions sessions. Join us as a Sponsor or Exhibitor and benefit from maximum visibility and exposure to a broad audience.
We look forward to welcoming as many participants as possible in Munich on-site by simultaneously reaching out to a wider and more international audience than ever before.
Copyrights © 2026 eMedEvents Corporation, All Rights Reserved